Amazon ramps up trademarks for pharmacy business

Amy Baxter | | Health Exec | Policy & Regulations
Some patients with certain autoimmune diseases in some states are finding it difficult to obtain their prescriptions for methotrexate as a result of changing abortion care laws.

Amazon is signaling it may soon sell prescription drugs in the U.K., Canada and Australia after the company moved to trademark “Amazon Pharmacy” in those countries at the start of 2020, CNBC reported.

According to trademark filings, Amazon may also move into surgical, medical dental instruments and pharmaceutical.

Amazon has continually increased its presence in the healthcare space, including acquiring online pharmacy PillPack in 2018 for $1 billion. The brand Amazon Pharmacy has begun to appear on printed materials and labels since the end of 2019.

While the trademark filing doesn’t mean Amazon has imminent plans to sell prescription medications, it does indicate the company’s desires to “go global,” CNBC reported.

See the full story below:

Amazon just filed a bunch of international trademarks for ‘Amazon Pharmacy’

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.